1. Scrip

Vascepa Gains European Filing Nod

No Rush In Search For Marketing Partner

 
• By Andrew McConaghie

On the cusp of US approval, Amarin must wait until late 2020 for EMA judgement

Blood_Test_Syringe
Approved in the US since 2012, Vascepa looks set to become a blockbuster

Amarin’s blockbuster-in-waiting cardiovascular treatment Vascepa is on the path to EU approval with a filing at the European Medicines Agency.

The EMA has validated Amarin’s marketing authorization application (MAA) for Vascepa (icosapent ethyl), to treat patients already taking statins but...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapy Areas

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 
• By Alaric DeArment

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

Santen Sees Potential In Myopia Market After Ryjunea Approval

 
• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

 
• By Andrew McConaghie

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.